Skip to main content
EMC Instytut Medyczny S.A. logo

EMC Instytut Medyczny S.A. — Investor Relations & Filings

Ticker · EMC ISIN · PLEMCIM00017 LEI · 2594005WSYZ0JRE8U796 WAR Human health and social work activities
Open in API
Filings indexed 786 across all filing types
Latest filing 2016-08-24 Audit Report / Informat…
Country PL Poland
Listing WAR EMC

About EMC Instytut Medyczny S.A.

https://www.emc-sa.pl/en

EMC Instytut Medyczny S.A. is a significant operator of private hospitals and outpatient clinics. The company provides comprehensive healthcare services through a network of medical facilities. Its operations are structured into three primary segments: Hospital Care, Outpatient Care, and Clinical Trials. The company offers a wide range of medical specializations, including dermatology, gastroenterology, and immunology. In addition to its core patient care services, EMC Instytut Medyczny is also actively engaged in conducting clinical research.

Recent filings

Filing Released Lang Actions
Raport Biegłego Rewidenta z przeglądu śrródrocznego skróconego skonsolidowanego sprawozdania finansowego Grupy EMC Instytut Medyczny
Audit Report / Information Classification · 99% confidence The document is titled "Raport niezależnego biegłego rewidenta z przeglądu śródrocznego skróconego skonsolidowanego sprawozdania finansowego za okres od 1 stycznia do 30 czerwca 2016 r." (Report of the independent auditor on the review of the condensed interim consolidated financial statements for the period from January 1 to June 30, 2016). This explicitly states it is an auditor's report concerning an interim (half-year) financial statement review. The content details the scope of the review (MSR 34, KSRF 2410) and concludes with the auditor's findings regarding the interim consolidated financial statements for the period ending June 30, 2016. This aligns perfectly with the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinguishing it from a full Annual Report (10-K) or a general Interim Report (IR) which would be the financial statements themselves, not the auditor's review opinion on them. The document length (4519 chars) is substantial enough to be the report itself, not just an announcement (RPA/RNS). H1 2016
2016-08-24 Polish
Raport Biegłego Rewidenta z przeglądu śródrocznego skróconego jednostkowego sprawozdania finansowego EMC Instytut Medyczny SA
Audit Report / Information Classification · 99% confidence The document is titled "Raport niezależnego biegłego rewidenta z przegladu śródrocznego skróconego jednostkowego sprawozdania finansowego" (Independent Auditor's Report on the Review of the Condensed Half-Year Consolidated Financial Statements). It explicitly details the scope of a review performed on interim financial statements (for the period January 1 to June 30, 2016) and concludes with the auditor's findings. This content aligns perfectly with the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER). The document is the report itself, not an announcement of its publication. H1 2016
2016-08-24 Polish
Sprawozdanie Zarządu z działalności Grupy EMC Instytut Medyczny za I półrocze 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Sprawozdanie Zarządu z działalności' (Management Board Report on Activities) for the 6-month period ending June 30, 2016. It contains detailed information about the company structure, financial situation, management changes, and governance. Since it covers a period shorter than a full fiscal year (6 months) and includes substantive financial and operational analysis, it is classified as an Interim/Quarterly Report (IR). H1 2016
2016-08-24 Polish
Śródroczne skrócone skonsolidowane sprawozdanie finansowe i jednostkowe sprawozdanie finansowe Grupy EMC Instytut Medyczny i EMC Instytut Medyczny SA za I półrocze 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Śródroczne skrócone skonsolidowane i jednostkowe sprawozdanie finansowe' (Interim condensed consolidated and separate financial statements) for the period ending June 30, 2016. It contains detailed financial statements, including balance sheets, income statements, cash flow statements, and extensive explanatory notes. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2016
2016-08-24 Polish
Rozmowy prowadzone w celu zawarcia umowy nabycia udziałów - Content (PL)
M&A Activity Classification · 98% confidence The document text, written in Polish, discusses potential negotiations regarding the acquisition of 100% of the shares of another medical company ("Certus"). It explicitly states that this information is confidential and price-sensitive, referencing Article 17(1) of the MAR Regulation (EU) No 596/2014. This type of announcement regarding a potential merger or takeover activity falls under the category of M&A Activity (TAR). The document is a formal regulatory disclosure about a significant corporate transaction.
2016-08-11 Polish
Nabycie udziałów Spółki Q-Med spółka z ograniczoną odpowiedzialnością z siedzibą w Oleśnicy oraz CM Medyk spółka z ograniczoną odpowiedzialnością z siedzibą we Wrocławiu - Content (PL)
M&A Activity Classification · 99% confidence The document text, written in Polish, details the acquisition of 100% of the shares in two medical companies (Q-Med and CM Medyk) by EMC Instytut Medyczny S.A. It specifies the transaction dates, the number of shares, the purchase price, and the methodology for adjusting the price based on net debt. Crucially, the document concludes by stating that this information constitutes inside information under MAR (Regulation (EU) No 596/2014) and is being disclosed under Article 17(1) of that regulation. This structure—a detailed announcement of a significant corporate event (acquisition/transaction) followed by a reference to MAR Article 17—is characteristic of a mandatory regulatory disclosure concerning a major transaction or change in corporate structure. Since the document is a direct announcement of a significant event rather than a general report or a proxy statement, and it doesn't fit perfectly into the specific categories like Director's Dealing (DIRS) or Dividend Notice (DIV), it falls best under the general regulatory disclosure category, which is 'Regulatory Filings' (RNS), as it is a mandatory disclosure under EU market abuse regulation (MAR). However, given the nature of the transaction (acquisition of control/major asset purchase), it strongly relates to capital structure changes or major corporate events. Since 'M&A Activity' (TAR) is defined as 'Announcements and documents related to merger proposals or takeover bids,' and this is a completed acquisition, TAR is a strong candidate. Given the context of mandatory disclosure under MAR for material non-public information, RNS is the safest general regulatory bucket, but TAR specifically covers M&A. I will classify it as TAR because the core subject is the acquisition of control over other companies, which is a form of M&A activity.
2016-08-01 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.